National Research Corp (NRC) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
National Research Corp stock (NRC) is currently trading at $17.18. National Research Corp PE ratio is 35.02. National Research Corp PS ratio (Price-to-Sales) is 2.90. WallStSmart rates NRC as Sell.
- NRC PE ratio analysis and historical PE chart
- NRC PS ratio (Price-to-Sales) history and trend
- NRC intrinsic value — DCF, Graham Number, EPV models
- NRC stock price prediction 2025 2026 2027 2028 2029 2030
- NRC fair value vs current price
- NRC insider transactions and insider buying
- Is NRC undervalued or overvalued?
- National Research Corp financial analysis — revenue, earnings, cash flow
- NRC Piotroski F-Score and Altman Z-Score
- NRC analyst price target and Smart Rating
National Research Corp
📊 No data available
Try selecting a different time range
NRC Intrinsic Value Analysis for Value Investors
Benjamin Graham Formula · National Research Corp (NRC)
NRC trades 304% above its Graham fair value of $3.40, indicating the stock may be overvalued at current levels.
Based on Benjamin Graham Formula. Growth rate capped at 25%. For informational purposes only. Not financial advice.
Smart Analysis
National Research Corp (NRC) · 9 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in return on equity, operating margin. Concerns around price/book and revenue growth. Mixed signals suggest waiting for clearer direction before acting.
National Research Corp (NRC) Key Strengths (2)
Every $100 of shareholder equity generates $51 in profit
Keeps $32 of every $100 in revenue after operating costs
National Research Corp (NRC) Areas to Watch (7)
Revenue declining -4.60%, a shrinking business
Earnings declining -74.40%, profits shrinking
Very expensive at 28.2x book value
Thin profit margins with limited profitability
Small-cap company with higher risk but more growth potential
Revenue is fairly priced at 2.90x sales
Moderate institutional interest at 48.25%
Supporting Valuation Data
National Research Corp (NRC) Detailed Analysis Report
Overall Assessment
This company scores 42/100 in our Smart Analysis, earning a D grade. Out of 9 metrics analyzed, 2 register as strengths (avg 10.0/10) while 7 fall into concern territory (avg 3.3/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Return on Equity, Operating Margin. Profitability is solid with Return on Equity at 51.20%, Operating Margin at 32.20%.
The Bear Case
The primary concerns are Revenue Growth, EPS Growth, Price/Book. Some valuation metrics including Price/Sales (2.90), Price/Book (28.16) suggest expensive pricing. Growth concerns include Revenue Growth at -4.60%, EPS Growth at -74.40%, which may limit upside. Profitability pressure is visible in Profit Margin at 8.44%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Revenue Growth improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at 51.20% currently healthy but needing to be sustained. Third, growth sustainability, with Revenue Growth at -4.60% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Revenue Growth and EPS Growth are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
NRC Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
NRC's Price-to-Sales ratio of 2.90x trades 48% below its historical average of 5.54x (13th percentile). The current valuation is 77% below its historical high of 12.6x set in Dec 2019, and 71% above its historical low of 1.7x in Apr 2025. Over the past 12 months, the PS ratio has expanded from ~2.0x, reflecting growing market expectations outpacing revenue growth.
WallStSmart Analysis Synopsis
Data-driven financial summary for National Research Corp (NRC) · HEALTHCARE › HEALTH INFORMATION SERVICES
The Big Picture
National Research Corp operates as a stable business with moderate growth and solid fundamentals. Revenue reached 137M with 460% decline year-over-year. Profit margins are thin at 8.4%, typical for companies in this phase that are reinvesting heavily in growth.
Key Findings
ROE of 5120.0% means the company generates strong returns on shareholder equity. Above 20% is considered top-tier.
Generating 6M in free cash flow and 7M in operating cash flow. Earnings are translating into actual cash generation.
Revenue contracted 460% YoY. Worth determining whether this is cyclical or structural.
What to Watch Next
Margin expansion: can National Research Corp push profit margins above 15% as the business scales?
Sector dynamics: monitor HEALTH INFORMATION SERVICES industry trends, competitive moves, and regulatory changes that could impact National Research Corp.
Bottom Line
National Research Corp offers stability with moderate growth and solid fundamentals. The valuation may present an opportunity for patient investors, though limited growth means returns will likely come from dividends and modest capital appreciation rather than explosive gains.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About National Research Corp(NRC)
NASDAQ
HEALTHCARE
HEALTH INFORMATION SERVICES
USA
National Research Corporation provides analytics and information that make it easy to measure and improve the patient and employee experience in the United States and Canada. The company is headquartered in Lincoln, Nebraska.